Emergent Biosolutions Company Profile (NYSE:EBS)

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent Biosolutions, Inc. (NYSE:EBS) announced its quarterly earnings data on Thursday, May, 4th. The company reported $0.23 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.31 by $0.08. The company had revenue of $116.90 million for the quarter, compared to analysts' expectations of $121.30 million. Emergent Biosolutions had a return on equity of 11.92% and a net margin of 10.36%. The company's revenue was up 13.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.16 earnings per share. View Emergent Biosolutions' Earnings History.

4 brokerages have issued 1-year price targets for Emergent Biosolutions' stock. Their forecasts range from $33.00 to $47.00. On average, they expect Emergent Biosolutions' stock price to reach $39.25 in the next year. View Analyst Ratings for Emergent Biosolutions.

Here are some recent quotes from research analysts about Emergent Biosolutions stock:

• 1. According to Zacks Investment Research, "Emergent’s key drug BioThrax is from the company’s Biodefense segment. The U.S. government is the primary purchaser of its Biodefense products. Hence, the company’s sole dependence on BioThrax for its revenue is concerning. Moreover, Emergent faces competition from a number of companies with Biodefense products, which could adversely affect the company’s operating results. Shares of the company have underperformed the broader industry so far this year. However, the company’s follow-on contract with the CDC for BioThrax and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/17/2017)
• 2. Cowen and Company analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)
• 3. J P Morgan Chase & Co analysts commented, "This afternoon, Emergent announced 2Q financial results, and while a great deal of focus remains on the upcoming BioThrax and NuThrax contracts, details were limited on these topics and 2016 guidance will not be reinstated until the outcomes are known. While we continue to see high probability of approval for Building 55 (Aug 15 PDUFA date), we believe the Street will need incremental clarity, particularly visibility on pricing in the next BioThrax contract and some color on expectations for the near-term delivery schedule, for the overhang on EBS shares to begin to lift. That said, this clarity is not far off, and we expect an update on both BioThrax and NuThrax by the end of September." (8/5/2016)

Some companies that are related to Emergent Biosolutions include Intrexon Corporation (XON), Ligand Pharmaceuticals Incorporated (LGND), Ironwood Pharmaceuticals (IRWD), FibroGen (FGEN), Blueprint Medicines Corporation (BPMC), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Genus plc (GNS), Immunomedics (IMMU), Cellectis S.A. (CLLS), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Heron Therapeutics (HRTX) and Arena Pharmaceuticals (ARNA).

Emergent Biosolutions' management team includes the folowing people:

• Fuad El-Hibri, Executive Chairman of the Board
• Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director
• Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer
• Adam Havey, Executive Vice President - Business Operations
• Ronald B. Richard, Lead Independent Director
• Sue Bailey M.D., Independent Director
• Zsolt Harsanyi Ph.D., Independent Director
• Jerome M. Hauer, Independent Director
• George A. Joulwan USA, Independent Director

Emergent Biosolutions' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.97%), Peregrine Capital Management LLC (0.79%), Bank of Montreal Can (0.21%), US Bancorp DE (0.10%), Eqis Capital Management Inc. (0.09%) and Nisa Investment Advisors LLC (0.09%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Barry Labinger, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC, Adams Diversified Equity Fund Inc., Peregrine Capital Management LLC, Capstone Asset Management Co., Nisa Investment Advisors LLC and US Bancorp DE. Company insiders that have sold Emergent Biosolutions stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Jerome M Hauer, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.

Emergent Biosolutions' stock was purchased by a variety of institutional investors in the last quarter, including Capital Asset Advisory Services LLC, State of Alaska Department of Revenue, Aperio Group LLC, Eqis Capital Management Inc., Louisiana State Employees Retirement System and Creative Planning. View Insider Buying and Selling for Emergent Biosolutions.

Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Emergent Biosolutions stock can currently be purchased for approximately $35.91.